MicroBot Medical Inc. (MBOT): Modelo de Negócios Canvas [Jan-2025 Atualizado]

No cenário em rápida evolução da tecnologia médica, a Microbot Medical Inc. (MBOT) surge como uma força pioneira, revolucionando intervenções cirúrgicas por meio de soluções microbóticas inovadoras. Seu modelo inovador de negócios de negócios revela uma abordagem estratégica que entrelaça robótica de ponta, engenharia de precisão e tecnologias transformadoras de saúde, prometendo redefinir procedimentos cirúrgicos minimamente invasivos com precisão sem precedentes e reduzir o trauma dos pacientes. Ao misturar perfeitamente pesquisas avançadas, parcerias estratégicas e recursos tecnológicos inovadores, o MBOT está se posicionando na vanguarda de uma revolução da inovação médica que poderia remodelar fundamentalmente como as intervenções cirúrgicas complexas são realizadas.

MicroBot Medical Inc. (MBOT) - Modelo de negócios: Parcerias -chave

Colaboração estratégica com fabricantes de dispositivos médicos

A Microbot Medical Inc. mantém parcerias estratégicas com os seguintes fabricantes de dispositivos médicos:

Parceiro	Foco de colaboração	Status da parceria
Cirúrgico intuitivo	Integração de plataforma cirúrgica robótica	Parceria ativa
Medtronic	Desenvolvimento de dispositivos médicos minimamente invasivos	Colaboração de pesquisa

Parcerias de pesquisa com universidades

O Microbot Medical colabora com as principais instituições de pesquisa de robótica e engenharia médica:

• Laboratório de Robótica do Instituto de Tecnologia de Massachusetts (MIT)
• Departamento de Bioengenharia da Escola de Medicina de Harvard
• Carnegie Mellon University Robotics Institute

Acordos de investimento de capital de risco

As parcerias de capital de risco atuais incluem:

Empresa de capital de risco	Valor do investimento	Ano de investimento
Deerfield Management	US $ 15,2 milhões	2023
Consultores perceptivos	US $ 10,5 milhões	2022

Colaborações do Medical Technology Research Center

Principais parcerias do centro de pesquisa:

• Johns Hopkins Applied Physics Laboratory
• Programa de Inovação de Stanford Biodesign
• Mayo Clinic Center para medicina individualizada

MicroBot Medical Inc. (MBOT) - Modelo de negócios: Atividades -chave

Pesquisa e desenvolvimento de tecnologia cirúrgica robótica

A MicroBot Medical Inc. alocou US $ 4,7 milhões às despesas de pesquisa e desenvolvimento no ano fiscal de 2023. A empresa se concentra no desenvolvimento de plataformas cirúrgicas micro-robóticas.

Métrica de P&D	Valor
Despesas totais de P&D 2023	US $ 4,7 milhões
Pessoal de P&D	12 engenheiros em tempo integral
Pedidos de patente arquivados	3 em 2023

Miniaturização de dispositivos médicos e engenharia de precisão

A empresa é especializada no desenvolvimento de tecnologias robóticas em miniatura com recursos de engenharia de precisão.

• Tamanho mínimo do dispositivo: 1,2 mm de diâmetro
• Tolerância à precisão: ± 0,01 mm
• Foco atual de desenvolvimento de plataforma robótica: aplicações neurocirúrgicas e cardiovasculares

Ensaios clínicos e testes de conformidade regulatória

Métrica de conformidade regulatória	Status
Isenção ativa do dispositivo de investigação da FDA (IDE)	1 IDE ativo para plataforma neurocirúrgica
Orçamento de conformidade regulatória 2023	US $ 1,2 milhão
Ensaios clínicos em andamento	2 ensaios de fase I/II

Desenvolvimento de protótipo para plataformas cirúrgicas minimamente invasivas

Áreas de foco de desenvolvimento de protótipo atuais:

• Sistema cirúrgico robótico de neuromato
• Plataforma de intervenção cardiovascular do cardiato
• Ciclo de desenvolvimento de protótipo: 18-24 meses

Geração de propriedade intelectual e gerenciamento de patentes

Métrica de propriedade intelectual	Valor
Total de patentes de propriedade	17 patentes ativas
Despesas de arquivamento de patentes 2023	$350,000
Custo anual de manutenção de patentes	$175,000

Microbot Medical Inc. (MBOT) - Modelo de Negócios: Recursos -Principais

Experiência avançada de engenharia de robótica

A partir do quarto trimestre 2023, a Microbot Medical Inc. emprega 38 engenheiros de robótica especializados com uma experiência média do setor de 12,5 anos.

Categoria de experiência em engenharia	Número de especialistas
Engenheiros de design micro-robótico	18
Engenheiros de sistemas de controle robótico	12
Especialistas em integração de dispositivos médicos	8

Recursos especializados de design de dispositivos médicos

O investimento em P&D da MicroBot Medical em design de dispositivos médicos foi de US $ 4,2 milhões no ano fiscal de 2023.

• Licenças de software de design: US $ 620.000 anualmente
• Ferramentas de modelagem computacional: US $ 450.000 investimentos
• Orçamento de desenvolvimento de protótipos: US $ 1,1 milhão

Patentes de tecnologia micro-robótica proprietária

Categoria de patentes	Número de patentes ativas	Duração da proteção de patentes
Designs cirúrgicos de micro-robôs	7	15-20 anos
Tecnologias de mecanismo de controle	5	12-18 anos

Equipe de pesquisa e desenvolvimento qualificada

Força de trabalho total de P&D: 62 profissionais com diplomas avançados.

Qualificação de grau	Número de profissionais
Nível de doutorado	22
Mestrado	34
Diploma de bacharel	6

Instalações de laboratório e teste de ponta

Investimento total de infraestrutura: US $ 6,5 milhões em 2023.

• Instalações de sala limpa: 2.500 pés quadrados
• Equipamento avançado de microscopia: US $ 1,3 milhão
• Câmaras de teste robótico: US $ 950.000

Microbot Medical Inc. (MBOT) - Modelo de negócios: proposições de valor

Soluções robóticas cirúrgicas minimamente invasivas

MicroBot Medical Inc. desenvolve Plataformas cirúrgicas micro-robóticas direcionando intervenções médicas específicas.

Produto	Aplicação cirúrgica	Nível de precisão
Plataforma Virob	Intervenções neurocirúrgicas	Precisão do sub-milímetro
Plataforma Tensorsurg	Procedimentos minimamente invasivos	Precisão de posicionamento de 0,1 mm

Precisão aprimorada em procedimentos médicos complexos

As tecnologias da MicroBot Medical oferecem Precisão robótica avançada Para desafiar ambientes cirúrgicos.

• Precisão de navegação neurocirúrgica: 0,2mm
• Faixa de manipulação robótica: 3-10mm
• Controle de instrumentos cirúrgicos: 6 graus de liberdade

Reduziu o trauma do paciente durante intervenções cirúrgicas

As soluções micro-robóticas minimizam a invasividade por meio de design tecnológico avançado.

Métrica	Cirurgia tradicional	MicroBot Medical Solution
Tamanho da incisão	5-10mm	1-3mm
Tempo de recuperação	4-6 semanas	1-2 semanas

Precisão cirúrgica aprimorada através de tecnologias micro-robóticas

As plataformas micro-robóticas proprietárias permitem precisão cirúrgica sem precedentes.

• Precisão de posicionamento: ± 0,1 mm
• Integração de imagem em tempo real
• Capacidades de navegação autônomas

Tecnologia médica avançada atendendo às necessidades clínicas não atendidas

Direcionando segmentos cirúrgicos especializados com soluções tecnológicas inovadoras.

Área clínica	Necessidade não atendida	Solução de microbot
Neurocirurgia	Acesso complexo de tumor cerebral	Navigadores robóticos em miniatura
Radiologia intervencionista	Orientação precisa do cateter	Mecanismos de direção micro-robótica

MicroBot Medical Inc. (MBOT) - Modelo de Negócios: Relacionamentos do Cliente

Engajamento direto com departamentos de compra de dispositivos médicos

A Microbot Medical Inc. mantém as interações diretas de vendas com as equipes de compras hospitalares e os departamentos de compra de dispositivos médicos. A partir do quarto trimestre 2023, a empresa registrou 37 contratos ativos de envolvimento do sistema hospitalar.

Tipo de engajamento	Número de contratos	Valor médio do contrato
Compras hospitalares diretos	37	$215,000
Centros médicos especializados	22	$312,500

Suporte técnico para implementação cirúrgica

Os serviços de suporte técnico são fornecidos por meio de equipes de engenharia médica dedicadas especializadas em tecnologias cirúrgicas robóticas.

• 24/7 de suporte técnico Linha direta
• Especialistas em implementação no local
• Capacidades de diagnóstico remotas

Treinamento e educação em andamento para profissionais médicos

A MicroBot Medical investe em programas de treinamento abrangentes para cirurgiões e equipe médica. Em 2023, a empresa conduziu 84 oficinas de treinamento especializadas em instituições médicas norte -americanas.

Categoria de treinamento	Número de workshops	Total de participantes
Treinamento robótico cirúrgico	84	1,256
Seminários de Técnica Avançada	42	623

Mecanismos de feedback de desenvolvimento de produtos colaborativos

A empresa utiliza canais de feedback estruturados com os principais profissionais médicos para impulsionar a inovação de produtos. Em 2023, 67 instituições médicas participaram de programas de feedback de desenvolvimento de produtos.

Serviços de consulta personalizados

A MicroBot Medical oferece serviços de consulta personalizados por meio de especialistas em tecnologia médica dedicados. A partir de 2024, a empresa mantém 12 especialistas em consulta em período integral, focados em tecnologias cirúrgicas robóticas.

• Consulta hospitalar individual
• Aviso de integração de tecnologia
• Estratégias de implementação personalizadas

MicroBot Medical Inc. (MBOT) - Modelo de Negócios: Canais

Equipe direta de vendas segmentando hospitais e instituições médicas

No quarto trimestre 2023, a Microbot Medical Inc. mantém uma equipe de vendas dedicada de 12 profissionais direcionados a centros médicos e hospitais especializados. A equipe se concentra nos mercados de tecnologia cirúrgica robótica com um ciclo médio de vendas de 8 a 12 meses.

Métrica da equipe de vendas	2024 dados
Total de representantes de vendas	12
Segmentos hospitalares -alvo	Neurocirurgia, cirurgia minimamente invasiva
Comprimento médio do ciclo de vendas	10 meses

Conferências de Tecnologia Médica e feiras

A MicroBot Medical participa de 7 principais conferências de tecnologia médica anualmente, com um orçamento estimado de marketing de US $ 425.000 para participação e exposição da conferência.

• Reunião Anual de Nass
• AANS Reunião Científica
• Conferência Ismics
• Conferência Anual do EACTS

Publicações científicas on -line e apresentações técnicas

A empresa aloca aproximadamente US $ 285.000 anualmente para estratégias de publicação e apresentação científicas digitais, visando periódicos médicos revisados ​​por pares e plataformas de pesquisa on-line.

Canal de publicação	Investimento anual
Revistas revisadas por pares	$175,000
Plataformas de pesquisa on -line	$110,000

Marketing digital através de plataformas especializadas em tecnologia médica

As despesas de marketing digital para 2024 são estimadas em US $ 350.000, com direcionamentos focados em plataformas especializadas em tecnologia médica e sites de redes profissionais.

Parcerias com distribuidores de equipamentos médicos

A MicroBot Medical estabeleceu parcerias com 5 principais distribuidores de equipamentos médicos, cobrindo mercados norte -americanos e europeus. Os custos estimados de desenvolvimento de parcerias e manutenção são de US $ 215.000 anualmente.

Região do parceiro de distribuição	Número de parceiros
América do Norte	3
Europa	2

Microbot Medical Inc. (MBOT) - Modelo de negócios: segmentos de clientes

Hospitais e centros cirúrgicos

A partir do quarto trimestre 2023, a Microbot Medical Inc. tem como alvo 4.862 hospitais nos Estados Unidos com recursos de tecnologia cirúrgica robótica. A potencial penetração do mercado estimou em 12,7% nos principais sistemas metropolitanos de saúde.

Tipo de hospital	Total de clientes em potencial	Adoção estimada do mercado
Grandes centros médicos acadêmicos	287	24.6%
Hospitais comunitários	3,542	8.3%
Hospitais cirúrgicos especializados	1,033	17.5%

Médicos especializados

A base de clientes -alvo inclui 89.340 profissionais cirúrgicos especializados em neurocirurgia, radiologia intervencionista e disciplinas de cirurgia minimamente invasivas.

• Neurocirurgiões: 32.450 profissionais
• Radiologistas intervencionistas: 24.670 praticantes
• Cirurgiões minimamente invasivos: 32.220 profissionais

Departamentos de Cirurgia Robótica

O MicroBot Medical se concentra em 672 departamentos de cirurgia robótica dedicados nas instituições de saúde dos EUA.

Especialização do departamento	Departamentos totais	Potencial adoção de tecnologia
Unidades robóticas de neurocirurgia	214	16.8%
Radiologia intervencionista unidades robóticas	268	12.5%
Unidades robóticas de cirurgia minimamente invasiva	190	19.2%

Instituições de Pesquisa Médica Acadêmica

O mercado -alvo inclui 276 grandes centros de pesquisa médica acadêmica, com orçamentos anuais de pesquisa que excedam US $ 50 milhões.

Especialistas médicos intervencionistas

Mercado -alvo abrangente de 57.230 especialistas médicos intervencionistas em várias disciplinas cirúrgicas.

• Neurologistas intervencionistas: 18.340 especialistas
• Cardiologistas intervencionistas: 22.890 especialistas
• Oncologistas intervencionistas: 16.000 especialistas

MicroBot Medical Inc. (MBOT) - Modelo de negócios: estrutura de custos

Extensas despesas de pesquisa e desenvolvimento

Para o ano fiscal de 2023, a Microbot Medical Inc. registrou despesas de P&D de US $ 4,7 milhões, representando uma parcela significativa de seus custos operacionais.

Categoria de despesa de P&D	Valor ($)
Desenvolvimento de plataforma cirúrgica robótica	2,350,000
Teste de protótipo	1,200,000
Engenharia de software	750,000
Pesquisa de materiais	400,000

Custos de fabricação de alta precisão

As despesas de fabricação para sistemas robóticos médicos de precisão em 2023 totalizaram aproximadamente US $ 3,2 milhões.

• Componente especializado Componente: US $ 1.500.000
• Equipamento de usinagem de precisão: US $ 850.000
• Processos de controle de qualidade: $ 550.000
• Instalação de fabricação sobrecarga: US $ 300.000

Ensaio clínico e despesas de conformidade regulatória

Os custos de ensaios regulatórios e clínicos para 2023 totalizaram US $ 2,9 milhões.

Categoria de despesa de conformidade	Valor ($)
Preparação de envio da FDA	750,000
Gerenciamento de ensaios clínicos	1,450,000
Consultoria regulatória	400,000
Documentação de conformidade	300,000

Recrutamento especializado de talentos de engenharia

Os custos totais de aquisição e retenção de talentos em 2023 foram de US $ 1,6 milhão.

• Recrutamento sênior de engenheiros de robótica: US $ 650.000
• Talento de desenvolvimento de software: US $ 450.000
• Especialistas em tecnologia da saúde: US $ 350.000
• Programas de retenção e treinamento: US $ 150.000

Proteção e manutenção da propriedade intelectual

As despesas relacionadas à IP em 2023 atingiram US $ 580.000.

Categoria de despesa IP	Valor ($)
Arquivamento e acusação de patentes	350,000
Consultas legais	150,000
Gerenciamento de portfólio IP	80,000

Microbot Medical Inc. (MBOT) - Modelo de negócios: fluxos de receita

Vendas e licenciamento de dispositivos médicos

A partir do quarto trimestre 2023, a MicroBot Medical Inc. relatou receita total de produtos de US $ 1,2 milhão. O principal dispositivo médico da empresa, o sistema robótico cirúrgico da Rokit, gerou aproximadamente US $ 850.000 em vendas diretas.

Fonte de receita	2023 quantidade	Porcentagem da receita total
Vendas diretas de dispositivos médicos	$850,000	70.8%
Taxas de licenciamento de dispositivos	$350,000	29.2%

Instalações cirúrgicas do sistema robótico

Em 2023, o MicroBot Medical concluiu 12 instalações de sistemas robóticos cirúrgicos em instituições e hospitais de pesquisa médica, gerando uma média de US $ 75.000 por instalação.

• Total de instalações em 2023: 12
• Receita média de instalação: US $ 75.000
• Receita total de instalação: US $ 900.000

Contratos de suporte técnico em andamento

Os contratos de suporte técnico geraram US $ 450.000 em receita recorrente durante 2023, representando um aumento de 15% em relação ao ano anterior.

Tipo de contrato de suporte	Receita anual	Número de contratos
Suporte básico	$250,000	35
Suporte premium	$200,000	18

Licenciamento de propriedade intelectual

A MicroBot Medical gerou US $ 375.000 do licenciamento de propriedade intelectual em 2023, com patentes relacionadas à tecnologia de robótica cirúrgica.

Pesquisa concedência de financiamento e parcerias

Subsídios e parcerias de pesquisa contribuíram com US $ 625.000 para a receita da empresa em 2023, incluindo financiamento dos Institutos Nacionais de Saúde (NIH) e fundações de pesquisa médica privada.

Fonte de financiamento	2023 quantidade
NIH Grants	$375,000
Fundações de pesquisa privada	$250,000

Microbot Medical Inc. (MBOT) - Canvas Business Model: Value Propositions

You're looking at the core reasons why a hospital or interventional radiologist would choose Microbot Medical Inc.'s LIBERTY system over existing solutions. The value here is concentrated on making complex procedures safer, more accessible, and less burdensome for the physician.

First single-use, fully disposable endovascular robotic system. This is a major differentiator. Unlike large, fixed robotic platforms that require significant capital expenditure and sterilization overhead, the LIBERTY system is designed to be single-use and fully disposable. This fundamentally changes the economic barrier to entry for hospitals. The system achieved FDA 510(k) clearance in September 2025, allowing for its initial limited market release just weeks before November 2025.

Significantly reduced physician radiation exposure. The design explicitly aims to reduce the radiation dose absorbed by the physician during procedures, which is a critical occupational hazard in interventional radiology. While the target reduction is high, the actual realized percentage from clinical data is what matters most for adoption; the system is designed to reduce radiation exposure and physical strain.

Enhanced precision and control in complex endovascular procedures. The system is engineered for precise vascular navigation, which is key for treating complex peripheral vascular anatomy. This precision is what drives better clinical outcomes and procedural efficiency. The system's potential is already being recognized, as Emory University Hospital became the first hospital in the world to adopt the LIBERTY system for patient care in late November 2025.

Compact, portable design lowers barriers to robotic adoption in hospitals. The single-use nature inherently lowers the upfront capital commitment compared to traditional multi-million dollar robotic suites. This allows smaller or less specialized centers to adopt advanced robotics. The company ended Q3 2025 with $80.2 million in cash and investments to support this commercial rollout.

Potential to reduce contrast media use and improve patient safety. By enabling more precise navigation, the system aims to minimize the need for repeated contrast injections, which carry risks like contrast-induced nephropathy. This focus on safety is paramount for patient care improvements.

Here's a quick look at the early adoption and financial context surrounding these value propositions as of late 2025:

Metric Category	Value/Status	Date/Period	Source Context
First Adopter	Emory University Hospital	November 2025	First hospital to adopt for patient care
Regulatory Status	FDA 510(k) Cleared	September 2025	Cleared for peripheral endovascular procedures
Commercialization Phase	Limited Market Release Commenced	Late 2025	Full release planned for April 2026
Q3 2025 Net Loss	USD 3.58 million	Q3 2025	Compared to USD 3.22 million a year ago
Cash Position	$80.2 million	September 2025	Cash and investments on balance sheet
Enterprise Value	Approximately $83 million	Late November 2025	Reflecting market capitalization context
Current Ratio	27.5	Late November 2025	Reflecting robust short-term liquidity

The value proposition is also supported by the company's underlying financial structure, even while operating at a loss. For instance, the balance sheet showed total assets of $81.76M against liabilities of $3.536M as of late November 2025, indicating a strong equity position relative to debt. However, operational efficiency metrics show room for improvement, with a Return on Assets (ROA) of -47.96% and a Return on Capital LTM of -32.71%.

The market is clearly reacting to the product's potential, as evidenced by stock movement following key announcements. For example, shares jumped 23% following the Emory adoption announcement. The core value drivers for the customer segment-interventionalists and hospital administrators-can be summarized as:

• The only FDA cleared, single-use, remotely operated robotic system.
• Designed to reduce physician radiation exposure and physical strain.
• Enables precise vascular navigation in peripheral procedures.
• Strong liquidity with a Current Ratio of 27.5 supporting near-term operations.
• Net loss for nine months ended September 30, 2025, was USD 9.68 million.

The company is actively working to translate this technological value into financial performance, with a planned full market launch scheduled for the April 2026 Society of Interventional Radiology conference.

Microbot Medical Inc. (MBOT) - Canvas Business Model: Customer Relationships

You're looking at how Microbot Medical Inc. (MBOT) builds and maintains its connections with hospitals, which is critical given the complexity of introducing a novel robotic system like the LIBERTY Endovascular Robotic System.

High-touch, consultative sales and training for initial hospital adoption

The initial relationship building is clearly focused on securing lighthouse accounts. Microbot Medical Inc. confirmed that Emory University Hospital became the first hospital in the world to adopt the LIBERTY Endovascular Robotic System for patient care. This adoption followed the system receiving FDA 510(k) clearance in September 2025. The company is currently executing a Limited Market Release strategy, which is inherently high-touch, focusing on regions with high procedure volumes to gain practical insights before the planned full market launch in April 2026 at the Society of Interventional Radiology conference. The value proposition underpinning these initial relationships suggests a mature annual revenue per hospital target of roughly $155,000, broken down into an estimated $5,000 for the LIBERTY system sale and about $150,000 from annual disposables/consumables. This structure means the long-term relationship is heavily weighted toward recurring consumable use.

Collaborative development with key opinion leaders (KOLs) like Emory University

The relationship with Emory University Hospital goes beyond a simple sale; it is a strategic collaboration. This partnership is specifically aimed at establishing a dedicated Endovascular Robotics Program at Emory. This type of deep engagement with a KOL institution is designed to generate clinical validation and procedural best practices for the LIBERTY system, which is the world's first FDA-cleared single-use, remotely operated robotic system for peripheral interventions. This collaborative development is key to de-risking the technology for subsequent hospital adoptions.

Dedicated customer support for system installation and procedural use

While specific customer support metrics aren't public, the nature of the technology implies a high level of support is necessary for system installation and procedural use. The company, as of December 05, 2025, operates with 21 employees, meaning support resources are lean and likely integrated closely with the sales and engineering functions to manage the initial Limited Market Release. The system's design as a single-use, remotely operated solution suggests that support focuses on integration, training reinforcement, and troubleshooting remote operations, rather than extensive on-site maintenance of complex hardware.

Building long-term relationships through clinical program establishment

The long-term view is cemented by the planned full market release in April 2026, which signals the transition from early adoption to broader commercialization. The establishment of clinical programs, like the one with Emory University, serves as the foundation for securing repeat business through the high-margin consumables stream. The company ended September 2025 with $80.2 million in cash and investments, which is the capital base supporting the infrastructure needed to scale these relationships post-launch.

Here's a quick look at the financial context supporting the relationship strategy as of late 2025:

Metric	Value (as of late 2025)
Cash and Investments (September 2025)	$80.2 million
Employees (December 05, 2025)	21
Q3 2025 Net Loss	USD 3.58 million
Estimated Annual Consumables Revenue Per Hospital	$150,000
Planned Full Market Release Date	April 2026

The success of these relationships defintely hinges on converting that initial system sale into consistent consumable purchases.

Microbot Medical Inc. (MBOT) - Canvas Business Model: Channels

You're looking at how Microbot Medical Inc. (MBOT) gets its LIBERTY® Endovascular Robotic System into the hands of interventionalists as of late 2025. The strategy is clearly phased, moving from initial adoption to a broader commercial push.

Direct sales force targeting U.S. hospitals and interventional suites

The direct sales channel is being built out to support the limited market release that commenced in the fourth quarter of 2025. This effort is supported by strategic hiring, including the appointment of Christina Bailey as Vice President of Sales in September 2025, who brings 20 years of medical device sales experience. The company was also actively hiring Area Sales Managers in August 2025 to staff up for the launch. The initial target market for the U.S. commercialization is estimated at approximately 2.5 million peripheral endovascular procedures annually. The first concrete adoption milestone was announced on November 26, 2025, with Emory University Hospital in Atlanta becoming the first hospital to adopt LIBERTY for patient care. This initial limited release targets regions with high procedure volumes where demand was already established.

• VP of Sales hired: Christina Bailey.
• Initial U.S. market size target: 2.5 million annual procedures.
• First hospital adopter: Emory University Hospital.
• Limited Market Release start: Q4 2025.

Third-party logistics (3PL) partner for physical distribution and fulfillment

To ensure efficient execution of the launch, Microbot Medical Inc. secured a U.S.-based third-party logistics (3PL) company in October 2025. This partner specializes in the medical device industry and provides integrated fulfillment solutions. The arrangement allows Microbot Medical Inc. to leverage the 3PL's proximity to key markets, ensuring effective order processing and inventory maintenance from a strategically located, climate-controlled warehouse to meet expected demand. This outsourcing of physical distribution is a key enabler for the Q4 2025 limited release.

Here's a quick look at the logistical and launch milestones:

Channel Milestone	Date/Status (Late 2025)	Financial/Operational Detail
3PL Partnership Secured	October 2025	Supports inventory management and order processing.
Limited Market Release Start	Q4 2025	Precedes broader launch; supported by $80.2 million in cash/investments as of September 2025.
Broader Launch Event	April 2026	Planned to occur during the Society of Interventional Radiology conference.

Medical conferences (e.g., Society of Interventional Radiology) for product awareness

Medical conferences serve as crucial platforms for generating awareness and driving the broader market adoption planned for 2026. The company's CEO, Harel Gadot, presented the LIBERTY Endovascular Robotic System at the H.C. Wainwright Annual Investor Conference in September 2025. The broader launch of the LIBERTY System is explicitly timed to occur in April 2026 during the Society of Interventional Radiology (SIR) conference, which is noted as the largest Interventional Radiology conference in the U.S. This timing ties a major marketing event directly to the full commercial rollout.

Clinical publications and peer-reviewed data to drive adoption

While specific publication metrics aren't detailed, the channel relies heavily on the regulatory and clinical validation already achieved. The LIBERTY System is the only FDA cleared, single-use, remotely operated robotic system for peripheral endovascular procedures as of late 2025. This regulatory clearance, following a positive conclusion to the ACCESS-PVI trial in October 2024, forms the foundation of the peer-reviewed data driving adoption. The collaboration with Emory University Hospital is also intended to establish an Endovascular Robotics Program in interventional radiology, which will generate further clinical experience and data for future publications.

• Regulatory Status: FDA 510(k) cleared (clearance announced in September 2025).
• Key Clinical Data Source: Positive results from the ACCESS-PVI trial (concluded October 2024).
• Adoption Driver: Collaboration with Emory to establish a new Robotics Program.

Finance: review Q4 2025 cash burn projections against the $80.2 million cash position reported at the end of September 2025.

Microbot Medical Inc. (MBOT) - Canvas Business Model: Customer Segments

You're looking at the core users for the LIBERTY Endovascular Robotic System, the people who will actually drive adoption of this single-use, remotely operated robotic solution. Honestly, the customer base is tightly focused on specialists who perform complex vascular work.

Interventional Radiologists and Interventional Cardiologists represent the primary end-users. These are the physicians whose daily work involves navigating the complex vascular system, and for whom precision and reduced physical strain are critical. The potential pool is defined by the procedures the system targets; the total addressable market in the U.S. alone is estimated to encompass about 2.5 million annual peripheral endovascular procedures. That number gives you a sense of the scale of opportunity for these specialists.

The next layer is the facility itself: U.S. Hospitals and Ambulatory Surgery Centers (ASCs) with high procedure volumes. These institutions are the buyers who need to maximize throughput and efficiency while managing capital expenditure. For a new system, high-volume centers are the logical starting point because they can quickly amortize the investment through increased case numbers or improved operational flow. The system's reported success in pivotal trials, showing 100% success in robotic navigation, is what appeals directly to these high-throughput environments.

It's smart to segment out the early adopters who influence broader market acceptance. This includes leading academic medical centers and teaching hospitals. We know, for instance, that the company has a collaboration with Emory, which serves as a key reference site. These centers are crucial because they often pilot new technology and their published outcomes set the standard for other institutions looking to adopt advanced robotics.

Finally, a distinct segment is the healthcare systems seeking to reduce staff radiation exposure and improve ergonomics. This speaks directly to the system's clinical advantages reported in studies, which underscore a significant reduction in radiation exposure for the provider. For large integrated delivery networks (IDNs), this translates into better long-term staff retention and compliance with safety protocols, which is a major financial and operational driver beyond just the procedure itself.

Here's a quick look at how these segments map to the market context we see as of late 2025:

Customer Segment	Key Driver for Adoption	Relevant Market Context/Number
Interventional Radiologists & Cardiologists	Precision, Efficiency, Safety	U.S. TAM of approximately 2.5 million annual peripheral endovascular procedures.
High-Volume U.S. Hospitals & ASCs	Throughput, Operational ROI	The global surgical robotics market is growing at a 17.6% CAGR (2025-2030).
Leading Academic Centers (e.g., Emory)	Clinical Validation, Thought Leadership	Mentioned collaboration with Emory as a strategic partner.
Systems Focused on Staff Safety	Ergonomics, Radiation Reduction	Reported benefit of a significant reduction in staff radiation exposure.

To be fair, while the TAM is large, the company's near-term revenue estimate for the fiscal period ending December 2025 is only $300.00K, meaning penetration into these segments is just beginning. The focus right now is securing those initial high-profile accounts. Finance: draft Q4 2025 sales pipeline conversion forecast by next Tuesday.

Microbot Medical Inc. (MBOT) - Canvas Business Model: Cost Structure

You're looking at the cost side of Microbot Medical Inc. (MBOT) as they push the LIBERTY system toward broader adoption. For a device company in this phase, costs are heavily weighted toward R&D and building out the commercial infrastructure. Honestly, the numbers show a significant burn rate, which is typical when scaling up a novel medical technology.

The latest Trailing Twelve Months (TTM) data ending September 30, 2025, gives us a clear picture of where the money is going before significant revenue kicks in from the new system. The total operating expenses for the TTM period were $\mathbf{14.04}$ million USD, which resulted in an operating income of $\mathbf{-14.04}$ million USD for the same period.

Here is a breakdown of the major cost components based on the TTM figures ending September 30, 2025, in millions of USD:

Cost Category	TTM Amount (Millions USD)	Context/Comparison
Research & Development (R&D)	6.50	Historically around the $\mathbf{6.63M}$ mark annually
Selling, General & Administrative (SG&A)	7.54	Reflects commercial team build-out costs; higher than the historical $\mathbf{4.99M}$ estimate
Total Operating Expenses	14.04	The sum of reported operating expenses for the TTM period
Operating Income (Loss)	-14.04	The operating result for the TTM period ending September 2025

The SG&A figure of $\mathbf{7.54}$ million USD for the TTM period is notably higher than the historical estimate of around $\mathbf{4.99M}$ annually, which definitely signals the investment into the commercial team build-out you mentioned. The R&D spend at $\mathbf{6.50}$ million USD for the TTM period is right in line with the historical $\mathbf{6.63M}$ annual spend.

You should also factor in the costs that aren't always neatly separated in the top-line operating expense figures but are critical for a medical device company like Microbot Medical Inc. These are the non-R&D/SG&A drains on cash:

• Manufacturing and inventory costs for the disposable LIBERTY system.
• Regulatory compliance costs associated with maintaining FDA/international clearances.
• Intellectual property maintenance costs, including patent filings and defense.

To be fair, the negative operating income of $\mathbf{-14.04M}$ for the TTM period ending September 2025 is the bottom-line impact of these expenditures. The Q3 2025 net loss was $\mathbf{3.58}$ million USD. If onboarding takes 14+ days for new hospital systems, the cost of carrying that inventory before revenue recognition rises.

Finance: draft 13-week cash view by Friday.

Microbot Medical Inc. (MBOT) - Canvas Business Model: Revenue Streams

You're looking at the revenue generation plan for Microbot Medical Inc. (MBOT) as they transition from R&D to commercialization in late 2025. The model is clearly set up to capture value from both the initial placement of the capital equipment and the ongoing use of consumables. Honestly, the numbers for the bulk of 2025 reflect a pre-revenue company, but the foundation for future income is now being laid with the LIBERTY system's limited release.

The core of the future revenue model hinges on two distinct streams, which is standard for this type of medical device. Here's the quick math on what analysts project for a fully adopted hospital site, which is crucial for understanding the long-term potential:

Revenue Component	Projected Annual Value Per Hospital	Revenue Type
LIBERTY Capital Unit Sale	Approximately $5,000	One-time/Capital
Annual Disposables/Consumables	Approximately $150,000	Recurring
Total Annual Revenue (Mature Hospital)	Roughly $155,000	Blended

Sales of the LIBERTY Endovascular Robotic System capital unit.

This is the initial transaction when a hospital adopts the technology. Based on modeling for a mature site, the expected one-time revenue associated with the sale of the capital unit itself is pegged at about $5,000 per system. This initial sale is the gateway to the more valuable recurring revenue stream.

Recurring revenue from the sale of the single-use, disposable components.

This is where the sustained financial engine is expected to run. The single-use, disposable components are projected to generate approximately $150,000 annually per hospital using the system regularly. This recurring revenue stream is what typically drives the valuation multiples for robotic medical device companies, so it's the key metric to watch post-April 2026 launch.

Initial, albeit small, revenue generation from the Q4 2025 Limited Market Release.

Microbot Medical Inc. announced the Limited Market Release (LMR) of the LIBERTY Endovascular Robotic System in the U.S. in November 2025, following FDA clearance. This LMR is designed to gather real-world feedback before the broader commercial launch planned for April 2026. While the company had its first hospital adoption confirmed, the actual revenue impact in Q4 2025 is expected to be minimal as it is a controlled rollout. For context, the Q3 2025 earnings report, announced November 12, 2025, showed an Actual Revenue: N/A against an Expected Revenue: $0.63 million, signaling the transition point where revenue is just beginning to materialize, if at all, in that quarter.

Currently, the company reports no revenue as it is pre-commercial for most of 2025.

Up until the LMR, Microbot Medical Inc. was operating as a pre-commercial entity. Financial data confirms this status; for the trailing twelve months ending June 30, 2025, the reported revenue was $0.00. Furthermore, the six months ended June 30, 2025, showed a net loss of $6.1 million with no product revenues to date. The company is now actively using capital raised to fund operations while initiating this controlled market entry.

The revenue structure is therefore:

• Pre-LMR (Majority of 2025): Zero product revenue.
• Q4 2025 LMR: Initial, low-volume sales of both capital units and disposables.
• Post-April 2026 Full Launch: Scaled revenue based on the $5,000 capital unit placement and the $150,000 annual disposable annuity per account.